CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Cash flows from operating activities:
Net loss	$ (466,456)	$ (65,761)	$ (199,228)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	27,324	172,223	155,538
Impairment of long-lived assets	232,336	0	319,246
Provision for bad debt expense	0	678	3,852
Amortization of premium/discount on purchased securities	(95)	87	302
Write-down of inventory	19,767	5,176	0
(Gain) loss on disposal of fixed assets	0	(99)	265
Non-cash equity-based compensation expense	19,198	19,916	23,664
Non-cash IPR&D expense	18,029	0	945
Loss on debt extinguishment	0	35,922	10,926
Amortization of debt discount and debt issuance costs	15,242	15,658	14,395
(Gain) loss on sale of marketable securities, net	(265)	(1)	70
Change in fair value of contingent consideration	(270)	(49,607)	(47,686)
Deferred income taxes	404	41,166	(178,421)
Non-cash lease expense	2,725	0	0
Gain on sale of the CBR business	0	(87,076)	0
Transaction costs	0	(14,111)	0
Changes in operating assets and liabilities:
Accounts receivable, net	(18,816)	16,995	(14,978)
Inventories	(19,253)	(454)	(2,331)
Prepaid and other current assets	(113)	(6,097)	(2,222)
Accounts payable and accrued expenses	52,747	(32,568)	16,834
Deferred revenues	(6,400)	8,658	17,080
Payment of contingent consideration in excess of acquisition date fair value	0	0	(10,432)
Other assets and liabilities	(1,800)	95	(1,223)
Net cash (used in) provided by operating activities	(125,696)	60,800	106,596
Cash flows from investing activities:
Proceeds from sales or maturities of marketable securities	98,321	85,342	294,957
Purchases of marketable securities	(14,815)	(89,956)	(127,249)
Proceeds from the sale of the CBR business	0	519,303	0
Note receivable	0	(10,000)	0
Capital expenditures	(2,544)	(2,534)	(8,988)
Net cash provided by investing activities	20,962	502,155	102,920
Cash flows from financing activities:
Long-term debt principal payments	0	(475,000)	(353,125)
Proceeds from 2022 Convertible Notes	0	0	320,000
Payments to repurchase 2019 Convertible Notes	(21,417)	0	(191,730)
Payment of premium on debt extinguishment	0	(28,054)	(625)
Proceeds to settle warrants	0	0	323
Payment of convertible debt issuance costs	0	0	(9,553)
Payment of contingent consideration	(72)	(119)	(39,793)
Payments for repurchases of common stock	(13,730)	0	(19,466)
Proceeds from the issuance of common stock under the ESPP	1,506	0	0
Proceeds from the exercise of common stock options	30	3,881	3,021
Payments of employee tax withholding related to equity-based compensation	(1,830)	(2,682)	(2,696)
Net cash used in financing activities	(35,513)	(501,974)	(293,644)
Net (decrease) increase in cash, cash equivalents and restricted cash	(140,247)	60,981	(84,128)
Cash, cash equivalents and restricted cash at beginning of the year	253,751	192,770	276,898
Cash, cash equivalents and restricted cash at end of the year	113,504	253,751	192,770
Supplemental data of cash flow information:
Cash (refunded) paid for taxes	(202)	5,345	5,296
Cash paid for interest	10,667	48,757	56,959
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease obligations	18,455
Settlement of note receivable in connection with Perosphere acquisition	10,000	0	0
Fair value of common stock issued in connection with the acquisition of the Intrarosa intangible asset			13,500
Vyleesi Products
Cash flows from investing activities:
Acquisition of intangible asset	(60,000)	0	0
Intrarosa
Cash flows from investing activities:
Acquisition of intangible asset	0	0	(55,800)
Endoceutics, Inc.
Non-cash investing and financing activities:
Fair value of common stock issued in connection with the acquisition of the Intrarosa intangible asset	0	0	12,555
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset	$ 0	$ 0	$ 9,300